.Pharmacolibrary.Drugs.ATC.J.J05AG03

Information

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection as part of antiretroviral therapy. Efavirenz is approved by regulatory agencies and remains in clinical use today as a component of combination therapy for HIV.

Pharmacokinetics

Typical pharmacokinetic model in healthy adult volunteers following oral single dosing

References

1. Duarte, H, et al., & Morais, J (2017). Population Approach to Efavirenz Therapy. Journal of pharmaceutical sciences 106(10) 3161–3166. DOI:10.1016/j.xphs.2017.06.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28622951

2. Csajka, C, et al., & Buclin, T (2003). Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical pharmacology and therapeutics 73(1) 20–30. DOI:10.1067/mcp.2003.22 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12545140

3. Kappelhoff, BS, et al., & Beijnen, JH (2005). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clinical pharmacokinetics 44(8) 849–861. DOI:10.2165/00003088-200544080-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16029069

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)